3.連結財務諸表及び主な注記

(1)連結貸借対照表

 

 

(単位:百万円)

 

前連結会計年度

(2024年7月31日)

当連結会計年度

(2025年7月31日)

資産の部

 

 

流動資産

 

 

現金及び預金

15,666

9,157

受取手形及び売掛金

4,038

5,038

電子記録債権

258

247

商品及び製品

5,292

6,311

仕掛品

619

675

原材料及び貯蔵品

806

864

その他

596

1,576

貸倒引当金

2

0

流動資産合計

27,275

23,870

固定資産

 

 

有形固定資産

 

 

建物及び構築物(純額)

2,157

2,082

機械装置及び運搬具(純額)

725

708

工具、器具及び備品(純額)

509

518

土地

1,190

1,194

リース資産(純額)

11

27

建設仮勘定

16

164

有形固定資産合計

4,609

4,696

無形固定資産

 

 

のれん

124

71

その他

52

49

無形固定資産合計

177

120

投資その他の資産

 

 

投資有価証券

3,037

2,450

繰延税金資産

351

515

その他

1,122

996

投資その他の資産合計

4,510

3,961

固定資産合計

9,298

8,778

資産合計

36,573

32,649

 

 

 

 

(単位:百万円)

 

前連結会計年度

(2024年7月31日)

当連結会計年度

(2025年7月31日)

負債の部

 

 

流動負債

 

 

支払手形及び買掛金

1,250

1,923

短期借入金

14,900

11,400

1年内返済予定の長期借入金

760

560

未払金

4,039

3,520

未払法人税等

1,384

1,494

賞与引当金

72

72

その他

755

1,034

流動負債合計

23,163

20,005

固定負債

 

 

長期借入金

1,231

671

退職給付に係る負債

384

378

その他

208

45

固定負債合計

1,824

1,096

負債合計

24,987

21,101

純資産の部

 

 

株主資本

 

 

資本金

2,043

2,043

資本剰余金

1,814

1,814

利益剰余金

8,356

7,691

自己株式

1,194

195

株主資本合計

11,019

11,353

その他の包括利益累計額

 

 

その他有価証券評価差額金

566

193

その他の包括利益累計額合計

566

193

純資産合計

11,585

11,547

負債純資産合計

36,573

32,649

 

E0248429290株式会社ファーマフーズ通期第1号参考様式 [日本基準](連結)Japan GAAPtrueCTECTE2024-08-012025-07-31FY2025-07-312023-08-012024-07-312024-07-311falsefalsefalse292902023-07-31jppfs_cor:CapitalStockMember292902023-07-31jppfs_cor:CapitalSurplusMember292902023-07-31jppfs_cor:RetainedEarningsMember292902023-07-31jppfs_cor:ValuationDifferenceOnAvailableForSaleSecuritiesMember292902023-08-012024-07-31jppfs_cor:CapitalStockMember292902023-07-31jppfs_cor:ShareholdersEquityMember292902023-07-31jppfs_cor:ValuationAndTranslationAdjustmentsMember292902023-08-012024-07-31jppfs_cor:CapitalSurplusMember292902023-08-012024-07-31jppfs_cor:RetainedEarningsMember292902023-08-012024-07-31jppfs_cor:ShareholdersEquityMember292902023-08-012024-07-31jppfs_cor:ValuationDifferenceOnAvailableForSaleSecuritiesMember292902023-08-012024-07-31jppfs_cor:ValuationAndTranslationAdjustmentsMember292902023-07-31292902023-08-012024-07-31292902025-09-11292902025-07-31292902024-08-012025-07-31292902024-07-31292902023-07-31jppfs_cor:TreasuryStockMember292902023-08-012024-07-31jppfs_cor:TreasuryStockMember292902023-08-012024-07-31jpcrp_cor:ReportableSegmentsMember292902025-07-31tse-acedjpfr-29290:BioMedicalReportableSegmentsMember292902024-08-012025-07-31jpcrp_cor:OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember292902023-08-012024-07-31jpcrp_cor:OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember292902025-07-31jpcrp_cor:ReportableSegmentsMember292902024-08-012025-07-31jpcrp_cor:ReportableSegmentsMember292902024-07-31jpcrp_cor:ReportableSegmentsMember292902023-08-012024-07-31tse-acedjpfr-29290:BtoBReportableSegmentsMember292902023-08-012024-07-31tse-acedjpfr-29290:BtoCReportableSegmentsMember292902023-08-012024-07-31tse-acedjpfr-29290:BioMedicalReportableSegmentsMember292902023-08-012024-07-31jpcrp_cor:ReconcilingItemsMember292902025-07-31tse-acedjpfr-29290:BtoBReportableSegmentsMember292902025-07-31tse-acedjpfr-29290:BtoCReportableSegmentsMember292902025-07-31jpcrp_cor:ReconcilingItemsMember292902024-08-012025-07-31tse-acedjpfr-29290:BtoBReportableSegmentsMember292902024-08-012025-07-31tse-acedjpfr-29290:BtoCReportableSegmentsMember292902024-08-012025-07-31tse-acedjpfr-29290:BioMedicalReportableSegmentsMember292902024-08-012025-07-31jpcrp_cor:ReconcilingItemsMember292902024-07-31tse-acedjpfr-29290:BtoBReportableSegmentsMember292902024-07-31tse-acedjpfr-29290:BtoCReportableSegmentsMember292902024-07-31tse-acedjpfr-29290:BioMedicalReportableSegmentsMember292902024-07-31jpcrp_cor:ReconcilingItemsMember292902023-08-012024-07-31jpcrp_cor:TotalOfReportableSegmentsAndOthersMember292902024-08-012025-07-31jpcrp_cor:TotalOfReportableSegmentsAndOthersMember292902024-08-012025-07-31jppfs_cor:CapitalStockMember292902024-07-31jppfs_cor:ValuationAndTranslationAdjustmentsMember292902024-07-31jppfs_cor:ValuationDifferenceOnAvailableForSaleSecuritiesMember292902024-07-31jppfs_cor:ShareholdersEquityMember292902024-07-31jppfs_cor:TreasuryStockMember292902024-07-31jppfs_cor:RetainedEarningsMember292902024-07-31jppfs_cor:CapitalSurplusMember292902024-07-31jppfs_cor:CapitalStockMember292902025-07-31jppfs_cor:ValuationAndTranslationAdjustmentsMember292902025-07-31jppfs_cor:ValuationDifferenceOnAvailableForSaleSecuritiesMember292902025-07-31jppfs_cor:ShareholdersEquityMember292902025-07-31jppfs_cor:TreasuryStockMember292902025-07-31jppfs_cor:RetainedEarningsMember292902025-07-31jppfs_cor:CapitalSurplusMember292902025-07-31jppfs_cor:CapitalStockMember292902024-08-012025-07-31jppfs_cor:ValuationAndTranslationAdjustmentsMember292902024-08-012025-07-31jppfs_cor:ValuationDifferenceOnAvailableForSaleSecuritiesMember292902024-08-012025-07-31jppfs_cor:ShareholdersEquityMember292902024-08-012025-07-31jppfs_cor:TreasuryStockMember292902024-08-012025-07-31jppfs_cor:RetainedEarningsMember292902024-08-012025-07-31jppfs_cor:CapitalSurplusMemberiso4217:JPYxbrli:pure